BMRN Stock Analysis — BioMarin Pharmaceutical
Sector: Healthcare
AI Verdict
BioMarin is cheap for the growth you're getting, but the moat around rare disease drugs needs to deliver on the huge earnings jump analysts expect.
Competitive Moat
BioMarin specializes in rare disease therapies, giving it pricing power and limited competition due to high barriers to entry in orphan drug development. Its portfolio of approved treatments and ongoing pipeline create a defensible position through regulatory exclusivity and specialist expertise.
Summary
BioMarin is drawing attention as its forward P/E drops to 13.3x on the back of a projected 170% EPS surge.
Where It Stands
BioMarin trades at 13.3x next year's earnings, a steep drop from its trailing 36.0x P/E, with analysts forecasting 170% EPS growth—making it look cheap relative to the healthcare sector median of 22x.
Key Metrics
- Trailing P/E: 36.0x
- Forward P/E: 13.3x
- PEG Ratio: 0.21
- Earnings Growth: +1.7%
- Revenue Growth: +0.1%
- 52-Week High: $70.98
- 52-Week Low: $49.26
Analyst Consensus
27 Buy · 8 Hold · 0 Sell (35 analysts)
Bull Case
A 170% forward EPS growth rate against a 13.3x forward P/E means you're paying a low price for explosive earnings momentum.
Bear Case
If the forward P/E reverts even halfway to its trailing 36.0x multiple, the stock could see a sharp rerating if growth disappoints.
Catalyst to Watch
Watch for clinical trial results or regulatory decisions that could confirm or derail the 170% EPS growth expectation.